Clinical Trials Browser

Phase 1 × INDUSTRY × cobimetinib × Clear all

NCT04835805 2026-02-03

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Phase 1 Active not recruiting

Melanoma

NCT04109456 2026-01-15

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT04190628 2024-05-21

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Phase 1 Terminated

CNSDermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03695380 2023-08-14

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Phase 1 Completed

Ovarian Neoplasms

NCT03284502 2023-08-01

HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Unknown

Neoplasm Metastasis

NCT02670044 2022-01-03

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03178851 2021-11-19

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

Phase 1 Completed

155 enrolled 22 charts

Melanoma

NCT01656642 2020-07-21

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT02876224 2019-08-13

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01271803 2019-07-29

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Phase 1 Completed

131 enrolled 32 charts

Melanoma

NCT02457793 2018-11-20

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

24 enrolled 27 charts

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT01974258 2016-11-02

Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients

Phase 1 Withdrawn

Neoplasms

NCT00467779 2016-08-26

Study of Cobimetinib in Participants With Solid Tumors

Phase 1 Completed

119 enrolled 63 charts

Other solid neoplasm

Solid Tumor

NCT01986166 2016-07-18

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

Phase 1 Completed

Neoplasms

NCT01562275 2016-03-28

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

67 enrolled 24 charts

Neoplasms